Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Piccolo presynaptic cytomatrix protein (PCLO) is a large, multi-domain scaffold protein highly concentrated at the presynaptic active zone of chemical synapses, where it plays a critical role in regulating the organization and function of synaptic vesicle trafficking, exocytosis, and synapse assembly[1][2][3][4]. PCLO is essential for synaptic structure and maintenance, and is highly expressed in the brain, neuromuscular junction, endocrine tissues, and various non-neural sites; it is implicated in processes as diverse as actin cytoskeleton dynamics, neurotransmitter and hormone secretion, and possibly gene expression regulation[2][3][1]. Mutations in PCLO are causative for pontocerebellar hypoplasia type III, and genetic variants are associated with major depressive disorder, bipolar disorder, and certain lymphomas[1][2][3]. There are currently no known therapeutic drugs directly targeting PCLO.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Piccolo presynaptic cytomatrix protein (PCLO).